{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:55:54Z","timestamp":1791971754974,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":111,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10553-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:37:16Z","timestamp":1782398236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ruxolitinib inhibits CaMKII-\u03b3 to reverse bortezomib resistance in multiple myeloma"],"prefix":"10.1038","volume":"9","author":[{"given":"Ruqi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xushan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0076-3069","authenticated-orcid":false,"given":"Mingdi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"10553_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410 (2021).","journal-title":"Lancet"},{"key":"10553_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70067","volume":"43","author":"F Gay","year":"2025","unstructured":"Gay, F., Marchetti, E. & Bertuglia, G. Multiple myeloma unpacked. Hematol. Oncol. 43, e70067 (2025).","journal-title":"Hematol. Oncol."},{"key":"10553_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae, A., van Rhee, F. & Al Hadidi, S. Perspectives on the treatment of multiple myeloma. Oncologist 29, 200 (2024).","journal-title":"Oncologist"},{"key":"10553_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327, 464 (2022).","journal-title":"JAMA"},{"key":"10553_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu, Q., Yang, D., Li, H., Niu, T. & Tong, A. Multiple myeloma: signaling pathways and targeted therapy. Mol. Biomed. 5, 25 (2024).","journal-title":"Mol. Biomed."},{"key":"10553_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/164_2017_10","volume":"249","author":"A Papadas","year":"2018","unstructured":"Papadas, A. & Asimakopoulos, F. Mechanisms of resistance in multiple myeloma. Handb. Exp. Pharm. 249, 251 (2018).","journal-title":"Handb. Exp. Pharm."},{"key":"10553_CR7","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00277-024-05730-y","volume":"103","author":"Q Chen","year":"2024","unstructured":"Chen, Q., Zhang, M., Zheng, S., Tong, Y. & Tan, Y. Therapeutic progress in relapsed\/refractory multiple myeloma. Ann. Hematol. 103, 1833 (2024).","journal-title":"Ann. Hematol."},{"key":"10553_CR8","doi-asserted-by":"publisher","first-page":"11725","DOI":"10.18632\/oncotarget.3955","volume":"6","author":"YY Wang","year":"2015","unstructured":"Wang, Y. Y., Zhao, R. & Zhe, H. The emerging role of CaMKII in cancer. Oncotarget 6, 11725 (2015).","journal-title":"Oncotarget"},{"key":"10553_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41583-022-00624-2","volume":"23","author":"R Yasuda","year":"2022","unstructured":"Yasuda, R., Hayashi, Y. & Hell, J. W. CaMKII: a central molecular organizer of synaptic plasticity, learning and memory. Nat. Rev. Neurosci. 23, 666 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"10553_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02030-7","volume":"21","author":"Q He","year":"2021","unstructured":"He, Q. & Li, Z. The dysregulated expression and functional effect of CaMK2 in cancer. Cancer Cell Int. 21, 326 (2021).","journal-title":"Cancer Cell Int."},{"key":"10553_CR11","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.18632\/aging.103490","volume":"12","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. CAMKII\u03b3 is a targetable driver of multiple myeloma through CaMKII\u03b3\/ Stat3 axis. Aging 12, 13668 (2020).","journal-title":"Aging"},{"key":"10553_CR12","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1182\/blood-2012-06-434894","volume":"120","author":"Y Gu","year":"2012","unstructured":"Gu, Y. et al. CaMKII \u03b3, a critical regulator of CML stem\/progenitor cells, is a target of the natural product berbamine. Blood 120, 4829 (2012).","journal-title":"Blood"},{"key":"10553_CR13","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/leu.2016.53","volume":"30","author":"Y Gu","year":"2016","unstructured":"Gu, Y. et al. Aberrant activation of CaMKII\u03b3 accelerates chronic myeloid leukemia blast crisis. Leukemia 30, 1282 (2016).","journal-title":"Leukemia"},{"key":"10553_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccell.2017.06.001","volume":"32","author":"Y Gu","year":"2017","unstructured":"Gu, Y. et al. Stabilization of the c-Myc protein by CAMKII\u03b3 promotes T cell lymphoma. Cancer Cell 32, 115 (2017).","journal-title":"Cancer Cell"},{"key":"10553_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-1138-4","volume":"19","author":"X Li","year":"2020","unstructured":"Li, X., He, S. & Ma, B. Autophagy and autophagy-related proteins in cancer. Mol. Cancer 19, 12 (2020).","journal-title":"Mol. Cancer"},{"key":"10553_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","volume":"17","author":"JMM Levy","year":"2017","unstructured":"Levy, J. M. M., Towers, C. G. & Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 17, 528 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"10553_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01628-4","volume":"22","author":"T Li","year":"2024","unstructured":"Li, T. et al. NCX1\/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NF\u03baB signaling pathway. Cell Commun. Signal 22, 258 (2024).","journal-title":"Cell Commun. Signal"},{"key":"10553_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10553_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-3-642-54490-3_16","volume":"201","author":"H Becker","year":"2014","unstructured":"Becker, H., Engelhardt, M., von Bubnoff, N. & W\u00e4sch, R. Ruxolitinib. Recent Results Cancer Res. 201, 249 (2014).","journal-title":"Recent Results Cancer Res."},{"key":"10553_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq7839","volume":"15","author":"OE Reyes Gaido","year":"2023","unstructured":"Reyes Gaido, O. E. et al. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci. Transl. Med. 15, eabq7839 (2023).","journal-title":"Sci. Transl. Med."},{"key":"10553_CR21","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.3390\/ijms21218323","volume":"21","author":"S Patergnani","year":"2020","unstructured":"Patergnani, S. et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int. J. Mol. Sci. 21, 8323 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"10553_CR22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cells10082125","volume":"10","author":"P Sukumaran","year":"2021","unstructured":"Sukumaran, P. et al. Calcium signaling regulates autophagy and apoptosis. Cells 10, 2125 (2021).","journal-title":"Cells"},{"key":"10553_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/15548627.2021.1954348","volume":"18","author":"Q Zhan","year":"2022","unstructured":"Zhan, Q. et al. CAMK2\/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux. Autophagy 18, 726 (2022).","journal-title":"Autophagy"},{"key":"10553_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102227","volume":"49","author":"H Guo","year":"2022","unstructured":"Guo, H. et al. Induction of autophagy via the ROS-dependent AMPK-mTOR pathway protects copper-induced spermatogenesis disorder. Redox Biol. 49, 102227 (2022).","journal-title":"Redox Biol."},{"key":"10553_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2021.06.029","volume":"520","author":"Z Jing","year":"2021","unstructured":"Jing, Z. et al. NCAPD2 inhibits autophagy by regulating Ca2+\/CAMKK2\/AMPK\/mTORC1 pathway and PARP-1\/SIRT1 axis to promote colorectal cancer. Cancer Lett. 520, 26 (2021).","journal-title":"Cancer Lett."},{"key":"10553_CR26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.bbrc.2006.05.066","volume":"345","author":"L Gao","year":"2006","unstructured":"Gao, L., Blair, L. A. & Marshall, J. CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels. Biochem. Biophys. Res. Commun. 345, 1606 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10553_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2017.06.016","volume":"403","author":"MB de Oliveira","year":"2017","unstructured":"de Oliveira, M. B. et al. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: a rationale for JAK\/STAT pathway inhibition in myeloma patients. Cancer Lett. 403, 206 (2017).","journal-title":"Cancer Lett."},{"key":"10553_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hon.3066","volume":"40","author":"JR Berenson","year":"2022","unstructured":"Berenson, J. R. et al. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed\/refractory multiple myeloma patients. Hematol. Oncol. 40, 906 (2022).","journal-title":"Hematol. Oncol."},{"key":"10553_CR29","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","volume":"26","author":"JR Berenson","year":"2020","unstructured":"Berenson, J. R. et al. A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed\/refractory multiple myeloma. Clin. Cancer Res. 26, 2346 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10553_CR30","first-page":"608","volume":"25","author":"LF Gu","year":"2017","unstructured":"Gu, L. F., Cui, X. G., Cao, X. M. & Chen, S. P. Drug-resistant mechanism of multiple myeloma and its therapy combined with HDACi -review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 25, 608 (2017).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10553_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun, F. et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat. Commun. 15, 615 (2024).","journal-title":"Nat. Commun."},{"key":"10553_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. PERSEUS trial investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10553_CR33","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802 (2024).","journal-title":"Am. J. Hematol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10553-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10553-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:38:51Z","timestamp":1791970731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10553-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10553"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10553-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1347"}}